KBC Group NV decreased its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 58.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 417,688 shares of the medical device company’s stock after selling 579,068 shares during the period. KBC Group NV owned 0.11% of DexCom worth $32,483,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. B. Riley Wealth Advisors Inc. grew its stake in DexCom by 4.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after purchasing an additional 162 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares in the last quarter. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the last quarter. Finally, Koa Wealth Management LLC raised its position in DexCom by 7.7% during the third quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after acquiring an additional 270 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.
DexCom Stock Performance
NASDAQ:DXCM opened at $87.53 on Tuesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a market cap of $34.19 billion, a price-to-earnings ratio of 52.41, a PEG ratio of 2.23 and a beta of 1.12. The stock has a fifty day moving average price of $79.50 and a 200-day moving average price of $76.88.
Insider Buying and Selling
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on DXCM. Canaccord Genuity Group boosted their price objective on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. JPMorgan Chase & Co. upped their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.29.
Read Our Latest Stock Report on DXCM
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
- Five stocks we like better than DexCom
- Best Stocks Under $10.00
- Sizing Up a New Opportunity for NVIDIA Investors
- Business Services Stocks Investing
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.